The Financials. Our latest release.

Find the latest quarterly results below.

2021-2022 Annual General Meeting

Chairperson's address

Good morning ladies and gentlemen, welcome and thank-you for joining our 2021 AGM. My name is Sue MacLeman and I am Chair of TALi Digital.

Healthier, happier minds have huge benefits for children, families and society.

TALi is a digital therapeutics business, with a patented evidence-based platform technology that is designed to treat cognitive inattention.

Our initial target population is the early childhood segment where the company has commercialised digital game-based attention screening and training programs – known collectively as TALi.

The Company has a multi-layered strategy to reach our customers, with a number of channels to market for our technology platform, across a range of global markets.

I August we announced a highly transformative landmark agreement with Akili Interactive Labs that will open up the prescription healthcare channel in the US, the world’s largest market for childhood ADHD treatment.

Over the year we have also focused on the continued strengthening of our go-to-market leadership, and commercial roll-out, with the initiation of marketing campaigns in India as well as refreshed marketing plans for Australia, New Zealand and Singapore.

With the worst of the COVID-19 pandemic now behind us due to the success of vaccination programs, we believe that the markets I have just mentioned offer significant potential for our Company, and now is the appropriate time to accelerate our growth plans.

While we are in the early stages of our global expansion and commercial roll-out, our recent entry into the US puts us in an advantageous position in local markets. We expect to be able to announce further milestones in the forward periods.

We also continue to explore new clinical indications and the potential for our core TALi technology to deliver benefits to patients, particularly as we look to expand our reach and impact into broader age groups. We are engaged in evaluating a research program to explore TALi’s applicability to other cognitive decline indications, more common in older age groups such as Mild Cognitive Impairment, which is often a precursor to Alzheimer’s. We will have more to say about developments in this area early next year.

As we move into a new and exciting period for our Company we begin FR2022 in a solid position. We are making good progress on our path towards building a base of sustainable long-term revenues for our shareholders.

From a funding and cash flow perspective, and as we stand today, we have approximately 4 quarters of cash available to fund our operations and commercialisation strategy.

I would like to acknowledge our management team and the entire TALi Digital workforce for they commitment and drive during what has been a challenging twelve months, as we have all continued to manage the impact of COVID-19 on our personal and professional lives.

I would also like to thank my fellow Board members for their ongoing commitment and guidance. Finally, thank-you to our shareholders who continue to support our company in its growth journey.

We look forward to sharing further updates with you as we execute further initiatives into 2022.

Sue MacLeman


First Quarter

Second Quarter

Third Quarter

Fourth Quarter

Annual Reports.

Annual Report 2023

Annual Report 2022

Annual Report 2021

Annual Report 2020